Clinical Trial Update: Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of carboplatin, a taxane, and ramucirumab for patients with non-small cell lung cancer after pemetrexed or p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Ramucirumab (ramucirumab)
• Taxane (paclitaxel or docetaxel)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING